Study of Combination Docetaxel and Radiotherapy With or Without Cisplatin to Treat Local Advanced Head and Neck Cancer
To evaluate the efficacy of the concomitant combination of radiotherapy and docetaxel with or without cisplatin in terms of objective response rates (WHO criteria).
Head and Neck Neoplasms
DRUG: docetaxel and cisplatin|DRUG: docetaxel
Objective response rates, evaluated 8 weeks after the end of radiotherapy
Duration of the responses and overall survival, time until progression
To evaluate the efficacy of the concomitant combination of radiotherapy and docetaxel with or without cisplatin in terms of objective response rates (WHO criteria).